Search - tctmd.com

Displaying 201 - 220 of 311

Sort: Relevancy | Date

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Caitlin E. Cox

May 02, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

Shelley Wood

April 30, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

Presentation Fellows 2024

High-Bleeding Risk Patient Who Needs Surgery after PCI

Presenter: Sanjum S. Sethi

April 13, 2024

Presentation Fellows 2024

Elective PCI Case: Prior CTA With High Calcium Score and MVD

Presenter: Darshan Doshi

April 13, 2024

Presentation Fellows 2024

ACS PCI Case: Loading, Timing, Transitions, and Other Issues

Presenter: Binita Shah

April 13, 2024

Presentation Fellows 2024

State-of-the-Art in NSTE-ACS: Management Strategies

Presenter: Binita Shah

April 12, 2024

Presentation Fellows 2024

Reperfusion Therapies in Myocardial Infarction: How Far We’ve Come

Presenter: David J. Cohen

April 12, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Presenter: Jacob Eifer Møller

April 07, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation ACC 2024

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Presenter: Gervasio A. Lamas

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

Caitlin E. Cox

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

Advertisement

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

TCTMD’s Top 10 Most Popular Stories for April 2024

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

High-Bleeding Risk Patient Who Needs Surgery after PCI

Elective PCI Case: Prior CTA With High Calcium Score and MVD

ACS PCI Case: Loading, Timing, Transitions, and Other Issues

State-of-the-Art in NSTE-ACS: Management Strategies

Reperfusion Therapies in Myocardial Infarction: How Far We’ve Come

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content